Innogen Pharmaceuticals
June 24, 2026
Theater 3
Type: Company Presentation
Focus Area:
Multiple Therapeutics
Innogen Pharmaceuticals is a HKex listed biopharma company based in China. Our leading asset, Efsubaglutide α, is with an half-life of 280 hours, enabling a once-MONTHLY dosing for weight management and is ready for Phase 3 trials in the US. Following its approval for type 2 diabetes in China, global BLA submissions are now underway. We are also building a robust and diversified pipeline, including a dual-action AD asset ready for FDA IND, a first-in-target asset leveraging Myokine for MASH, and a new drug for type 1 diabetes, and other new target obesity pipelines. Furthermore, our proprietary formulation technology is enabling an ultra-long-acting version with potential of semi-annual dosing.
Obesity: We are advancing Efsubaglutide α, which offers a compelling profile of significant fat loss, muscle preservation, and convenient once-monthly dosing regimen. Other first in class pipeline for obesity: Apelin/GLP-1, GCGRi/GLP-1, GHS-R…..
Company HQ City:
Shanghai
Company HQ State:
Shanghai
Company HQ Country:
China
Year Founded:
2014
Lead Product in Development:
Efsubaglutide α
CEO
Dr. Qinghua Wang
Development Phase of Lead Product
Multiple Products in Market
Number of Unlicensed Products Looking for Licensing
10
Exchange
HKEX
Ticker
2591.HK
When you expect your next catalyst update?
end of 2026
What is your next catalyst (value inflection) update?
Monthly dosing GLP-1RA phase 2 readout in Australia, phase 3 readout in China, AD FDA IND approval in future several months
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}